EUROPEAN JOURNAL OF

PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , Doi-Digital Online Identifier , ISSN National Centre , Zenodo Indexing , International CODEN Service, USA , 

 ISSN (O) : 2394-3211

 ISSN (P) : 3051-2573

Impact Factor: 8.158

ICV - 79.57

Abstract

A RETROSPECTIVE COMPARATIVE STUDY AND EVALUATION OF TUMOR BURDEN IN CONVENTIONAL VERSUS TRADITIONAL ANTI-NEOPLASTIC DRUGS

Dr. Mohd Minaz Pasha*, Dr. Fatema Arshi Saima, Dr. Shaik Fabiha Eestisam, Dr. Syed Mohammed Kazim

ABSTRACT

Background information: Cancer is a disease distinguished by uncontrollable or abnormal growth of cells resulting in the formation of malignant or benign tumors and suppressing the immune system, thereby deteriorating the quality of life of the host. The most common cause of mortality worldwide is “Cancer”, with an incidence of about 10 million deaths every year. India estimates about 14 61,427 cases roughly 100.4 per 100,000. With the increasing number of cancer cases, there is an advancement in its treatment as well. As the advancement in the treatment is seen, we also witness the serious side effects and ADRs connected with them, which are sometimes fatal to the patient. Therefore, it is necessary to have a rough idea about which drugs, either the traditional or the conventional, pose lesser side effects and are better choices for treating Cancer and improving a patient‟s quality of life. Aim: This study aims to compare the effectiveness of two drug classes for treating different types of cancer while assessing the tumor burden. The goal is to gain in-depth knowledge of the diseases and provide patients with effective treatment options. Objective: In this investigation, the patient with cancer will be extensively examined. To learn in-depth about the relevant illness and their condition. Demonstrating the patient's examination reports and the parameters with which we are going to assist the information already stored in the record room is going to be used in the thesis The treatment of cancer and the use of anti-neoplastic drugs should be evaluated. Method: A retrospective observational study evaluated the drugs to treat carcinoma in the Oncology department. Study period: The study was carried out for 6 months in Care hospital. Study population: The sample size consisted of 60-100 patients who qualified for the inclusion criteria for the study. Results: According to the study we analyzed 60 cases of Cancer patients out of which 34 cases were male and 26 were female between the age group of 9-80 years and the Cancer incidence rate in females was higher than in the male population. Some of them received the T drugs and few received C drugs, while the treatment cycle. Varied from 4-18. After a thorough investigation we found that both types of drugs were employed to treat Cancer and both of them were effective but the T drugs have much superior outcomes than the C drugs. Most Oncologists still prescribe the T drugs as before because of their fewer side effects, cost potency, and affordability by the patients. Conclusion: From the study, we can conclude that the prescribing pattern of the physicians still includes Traditional drugs such as Paclitaxel, Rituximab, Cisplatin, Carboplatin, 5FU, Zolendronic acid, and sometimes alongside other drugs. We found that traditional drugs had fewer side effects and were affordable to the patients. Conventional drugs were also used but not as often as the T drugs. In the coming years, we might see the increasing use of C drugs if they show lesser side effects with cost affordability. Another finding in the study that we came across was the patients with the blood group A+ were prone to Cancer in the 6 months, although this doesn‟t prove that the patients who belong to this blood group acquire Cancer commonly than the other blood group.

Keywords: .


[Full Text Article] [Download Certificate]

EJMPR Citation Report

  All Since 2021
 Citation  4339  2797
 h-index  23  20
 i10-index  109  52

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2026 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: NOVEMBER ISSUE PUBLISHED

    NOVEMBER 2026 issue has been successfully launched on 1 NOVEMBER 2026.

  • EJPMR: New Impact Factor 2026

    EJPMR Impact Factor has been Increased from 7.065 to 8.158, for Year 2026

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

BEST ARTICLE AWARDS

European Journal of Pharmaceutical and Medical Research is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Prof. Dr. Dhrubo Jyoti Sen
Download Article : Click Here

Google Scholar

Indian Science Publications

InfoBase Index (In Process)

SOCOLAR, China

Research Bible, Fuchu, Tokyo. JAPAN

International Society for Research activity (ISRA)

Scientific Indexing Services (SIS)

Polish Scholarly Bibliography

Global Impact Factor (GIF) (Under Process)

Universal Impact Factor

International Scientific Indexing (ISI), UAE

Index Copernicus

CAS (A Division of American Chemical Society) USA (Under Process)

Directory of Open Access Journal (DOAJ, Sweden, in process)

UDLedge Science Citation Index

CiteFactor

Directory Of Research Journal Indexing (DRJI)

Indian citation Index (ICI)

Journal Index (JI, Under Process)

Directory of abstract indexing for Journals (DAIJ)

Open Access Journals (Under Process)

Impact Factor Services For International Journals (IFSIJ)

Cosmos Impact Factor

Jour Informatics (Under Process)

Eurasian Scientific Journal Index (ESJI)

International Innovative Journal Impact Factor (IIJIF)

Science Library Index, Dubai, United Arab Emirates

Pubmed Database [NLM ID: 101669306] (Under Process)

IP Indexing (IP Value 2.40)

Web of Science Group (Under Process)

Directory of Research Journals Indexing

Scholar Article Journal Index (SAJI)

International Scientific Indexing ( ISI )

Scope Database

Academia

Doi-Digital Online Identifier

ISSN National Centre

Zenodo Indexing

International CODEN Service, USA